Over the past four decades, WCAS has successfully invested approximately $10 billion of equity in over 90 healthcare companies through its 13 private equity funds. WCAS's current portfolio includes market-leading healthcare businesses such as CenterWell and InnovAge.
About Valtruis
Ad Statistics
Times Displayed: 2147
Times Visited: 10 Fast-moving cardiac structures have a big impact on imaging. Fujifilm’s SCENARIA View premium performance CT brings solutions to address motion in Coronary CTA while delivering unique dose saving and workflow increasing benefits.
Valtruis, a WCAS portfolio company, provides a unique platform that invests in and partners with disruptive leaders whose mission is to align and transform healthcare through what is truly value-based care. Founded on a commitment to accelerate meaningful change, Valtruis brings the functional expertise, access to capital and an expansive network that advance our partners' evolution from early-stage development to industry-leading enterprises. Together, Valtruis and its partner companies will break through the systemic barriers in the healthcare industry to reduce costs, expand access, increase quality and radically improve the patient experience.
About Welsh, Carson, Anderson & Stowe
WCAS is a leading U.S. private equity firm focused on two target industries: technology and healthcare. Since its founding in 1979, the firm's strategy has been to partner with outstanding management teams and build value for its investors through a combination of operational improvements, growth initiatives and strategic acquisitions. The firm has raised and managed funds totaling over $27 billion of committed capital.
SOURCE Welsh, Carson, Anderson & Stowe
Back to HCB News
